Optimizing access to PrEP based on MSM preferences: results of a discrete choice experiment

References

• Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., … Ronald, A. (2012). Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. New England Journal of Medicine, 367(5), 399–410. doi: 10.1056/NEJMoa1108524
   PubMed Web of Science ®Google Scholar
• Bush, S., Magnuson, D., Rawlings, M. K., Hawkins, T., McCallister, S., & Mera Giler, R. (2016). Racial characteristics of FTC/TDF for pre-exposure prophylaxis (PrEP) users in the US. Boston, MA: ASM Microbe/ICAAC.
   Google Scholar
• Bush, S., Ng, L., Magnuson, D., Piontkowsky, D., & Mera Giler, R. (2015, June). Significant uptake of Truvada for pre-exposure prophylaxis (PrEP) utilization in the US in late 2014–1Q 2015. IAPAC treatment, prevention, and adherence conference (pp. 28–30) Miami, FL.
   Google Scholar
• Centers for Disease Control and Prevention. (2012). Vital signs: HIV infection, testing, and risk behaviors among youths-United States. Morbidity and Mortality Weekly Report, 61(47), 971.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. (2016a). HIV in the Southern United States. Issue brief.
   Google Scholar
• Centers for Disease Control and Prevention. (2016b). HIV surveillance report: Diagnoses of HIV infection in the United States and dependent areas, 2011, 2013.
   Google Scholar
• Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., … Chuachoowong, R. (2013). Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir study): A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 381(9883), 2083–2090. doi: 10.1016/S0140-6736(13)61127-7
   PubMed Web of Science ®Google Scholar
• Costa, P., Grivel, T., & Gehchan, N. (2009). Tadalafil once daily in the management of erectile dysfunction: Patient and partner perspectives. Patient Preference and Adherence, 3, 105–111. doi: 10.2147/PPA.S3937
   PubMed Web of Science ®Google Scholar
• Eaton, L. A., Driffin, D. D., Smith, H., Conway-Washington, C., White, D., & Cherry, C. (2014). Psychosocial factors related to willingness to use pre-exposure prophylaxis for HIV prevention among black men who have sex with men attending a community event. Sexual Health, 11(3), 244–251. doi: 10.1071/SH14022
   PubMed Web of Science ®Google Scholar
• Fonner, V. A., Dalglish, S. L., Kennedy, C. E., Baggaley, R., O'Reilly, K. R., Koechlin, F. M., … Grant, R. M. (2016). Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS, 30(12), 1973–1983. doi: 10.1097/QAD.0000000000001145
   PubMed Web of Science ®Google Scholar
• Golub, S. A., Kowalczyk, W., Weinberger, C. L., & Parsons, J. T. (2010). Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. Journal of Acquired Immune Deficiency Syndromes, 54(5), 548. doi: 10.1097/QAI.0b013e3181e19a54
   PubMed Web of Science ®Google Scholar
• Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., … Montoya-Herrera, O. (2010). Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New England Journal of Medicine, 363(27), 2587–2599. doi: 10.1056/NEJMoa1011205
   PubMed Web of Science ®Google Scholar
• Holmes, D. (2012). FDA paves the way for pre-exposure HIV prophylaxis. The Lancet, 380(9839), 325. doi: 10.1016/S0140-6736(12)61235-5
   PubMed Web of Science ®Google Scholar
• Horberg, M., & Raymond, B. (2013). Financial policy issues for HIV pre-exposure prophylaxis: Cost and access to insurance. American Journal of Preventive Medicine, 44(1), S125–S128. doi: 10.1016/j.amepre.2012.09.039
   PubMed Web of Science ®Google Scholar
• Huber, J., Orme, B., & Miller, R. (2007). The value of choice simulators. Conjoint measurement (pp. 347–362). New York, NY: Springer.
   Google Scholar
• Hurt, C. B., Eron Jr, J. J., & Cohen, M. S. (2011). Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clinical Infectious Diseases, 53(12), 1265–1270. doi: 10.1093/cid/cir684
   PubMed Web of Science ®Google Scholar
• Juusola, J. L., Brandeau, M. L., Owens, D. K., & Bendavid, E. (2012). The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Annals of Internal Medicine, 156(8), 541–550. doi: 10.7326/0003-4819-156-8-201204170-00001
   PubMed Web of Science ®Google Scholar
• Kavanaugh, M. L., Jerman, J., & Finer, L. B. (2015). Changes in use of long-acting reversible contraceptive methods among US women, 2009–2012. Obstetrics and Gynecology, 126(5), 917. doi: 10.1097/AOG.0000000000001094
   PubMed Web of Science ®Google Scholar
• Khanna, A. S., Michaels, S., Skaathun, B., Morgan, E., Green, K., Young, L., & Schneider, J. A. (2016). Preexposure prophylaxis awareness and use in a population-based sample of young black men who have sex with men. JAMA Internal Medicine, 176(1), 136–138. doi: 10.1001/jamainternmed.2015.6536
   PubMed Web of Science ®Google Scholar
• Löwe, B., Kroenke, K., & Gräfe, K. (2005). Detecting and monitoring depression with a two-item questionnaire (PHQ-2). Journal of Psychosomatic Research, 58(2), 163–171. doi: 10.1016/j.jpsychores.2004.09.006
   PubMed Web of Science ®Google Scholar
• Mayer, K. H., Oldenburg, C. E., Novak, D. S., Elsesser, S. A., Krakower, D. S., & Mimiaga, M. J. (2016). Early adopters: Correlates of HIV chemoprophylaxis use in recent online samples of US men who have sex with men. AIDS and Behavior, 20(7), 1489–1498. doi: 10.1007/s10461-015-1237-1
   PubMed Web of Science ®Google Scholar
• Meyers, K., Rodriguez, K., Moeller, R. W., Gratch, I., Markowitz, M., & Halkitis, P. N. (2014). High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: A P18 cohort substudy. PloS One, 9(12), e114700. doi: 10.1371/journal.pone.0114700
   PubMed Web of Science ®Google Scholar
• Orme, B. K. (2010). Getting started with conjoint analysis: Strategies for product design and pricing research. Madison, WI: Research Publishers.
   Google Scholar
• Parsons, J. T., Rendina, H. J., Whitfield, T. H., & Grov, C. (2016). Familiarity with and preferences for oral and long-acting injectable HIV pre-exposure prophylaxis (PrEP) in a national sample of gay and bisexual men in the US. AIDS and Behavior, 20(7), 1390–1399. doi: 10.1007/s10461-016-1370-5
   PubMed Web of Science ®Google Scholar
• Purcell, D. W., Johnson, C. H., Lansky, A., Prejean, J., Stein, R., Denning, P., … Crepaz, N. (2012). Suppl 1: Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates. The Open AIDS Journal, 6, 98. doi: 10.2174/1874613601206010098
   PubMedGoogle Scholar
• Saberi, P., Gamarel, K. E., Neilands, T. B., Comfort, M., Sheon, N., Darbes, L. A., & Johnson, M. O. (2012). Ambiguity, ambivalence, and apprehensions of taking HIV-1 pre-exposure prophylaxis among male couples in San Francisco: A mixed methods study. PloS One, 7(11), e50061. doi: 10.1371/journal.pone.0050061
   PubMed Web of Science ®Google Scholar
• Sawtooth Library. Retrieved from https://www.sawtoothsoftware.com/help/issues/ssiweb/online_help/index.html?hid_smrt_randomizedfirstchoice.htm
   Google Scholar
• Smith, D. K., Van Handel, M., & Huggins, R. (2017). Estimated coverage to address financial barriers to HIV preexposure prophylaxis among persons with indications for its use, United States, 2015. JAIDS Journal of Acquired Immune Deficiency Syndromes, 76(5), 465–472. doi: 10.1097/QAI.0000000000001532
   PubMed Web of Science ®Google Scholar
• Smith, D. K., Van Handel, M., Wolitski, R. J., Stryker, J. E., Hall, H. I., Prejean, J., … Valleroy, L. A. (2015). Vital signs: Estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition – United States, 2015. Morbidity and Mortality Weekly Report, 64(46), 1291–1295. doi: 10.15585/mmwr.mm6446a4
   PubMed Web of Science ®Google Scholar
• Tellalian, D., Maznavi, K., Bredeek, U. F., & Hardy, W. D. (2013). Pre-exposure prophylaxis (PrEP) for HIV infection: Results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. AIDS Patient Care and STDs, 27(10), 553–559. doi: 10.1089/apc.2013.0173
   PubMed Web of Science ®Google Scholar
• Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., … Chillag, K. L. (2012). Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. New England Journal of Medicine, 367(5), 423–434. doi: 10.1056/NEJMoa1110711
   PubMed Web of Science ®Google Scholar
• Van der Straten, A., Van Damme, L., Haberer, J. E., & Bangsberg, D. R. (2012). Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS, 26(7), F13–F19. doi: 10.1097/QAD.0b013e3283522272
   PubMed Web of Science ®Google Scholar
• Young, I., & McDaid, L. (2014). How acceptable are antiretrovirals for the prevention of sexually transmitted HIV? A review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention. AIDS and Behavior, 18(2), 195–216. doi: 10.1007/s10461-013-0560-7
   PubMed Web of Science ®Google Scholar